<DOC>
	<DOCNO>NCT02038933</DOCNO>
	<brief_summary>The purpose study determine whether Nivolumab effective treatment DLBCL patient fail ineligible ASCT</brief_summary>
	<brief_title>Study Nivolumab Patients With Relapsed Refractory Diffuse Large B-Cell Lymphoma ( DLBCL ) That Have Either Failed Are Not Eligible Autologous Stem Cell Transplant ( CheckMate 139 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Confirmation relapse refractory DLBCL transform lymphoma ( TL ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 At least one lesion measure &gt; 1.5 cm Prior therapy screen lab criterion must meet Appropriate contraceptive measure must take Known central nervous system ( CNS ) lymphoma History interstitial lung disease , prior malignancy , active autoimmune disease , positive test hepatitis B hepatitis C virus Prior allogeneic stem cell transplant ( SCT ) , chest radiation ≤ 24 week study drug , ≥1000 mg Carmustine Bischloroethylnitrosourea ( BCNU ) part pretransplant conditioning regimen , prior treatment drug target Tcell costimulation immune checkpoint pathway Women breastfeed pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>